A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC	Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma	Recruiting	Phase 2	2025-10-20		NCT06597565

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Acrivon Therapeutics	3
H. Lee Moffitt Cancer Center and Research Institute	162

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Moffitt Cancer Center	Tampa	United States	523

Clinical trials